Revolution: From Generics to Global Innovation, the Transformation Redefining the Geoeconomic Balance - Part II

The Geopolitics of Pharmaceuticals and the Mapping of Chinese Dominance

The Chinese biopharmaceutical industry is accelerating to complete a strategic industrial transformation, definitively surpassing its role as a leader in generic API production (with an estimated 80% control of the global supply chain in 2023) to establish itself as a global power in strategic innovation. As mentioned, this transition, in line with the objectives of the 14th Five-Year Plan, the Made in China 2025 initiative, and the draft 15th Five-Year Plan, generates a huge geopolitical advantage in the escalation with the United States.

GettyImages

China's rise, which has seen its R&D spending surpass that of the European Union and its sectoral revenues forecast to grow by 135% between 2020 and 2025, is structured on a strategy of specialized regional clusters that manages the entire value chain and its global integration:

• BTH Cluster (Beijing-Tianjin-Hebei): Serves as the nation's academic and R&D hub, essential for basic research and early-stage discovery. It leverages high-concentration centers like the Zhongguancun Life Science Park and drives the research that accounts for 23% of the world’s next-generation therapeutic candidates.

• Yangtze River Delta (YRD): Is the most dynamic hub for commercialization and large-scale manufacturing, leading the integration of AI and synthetic biology. The bio-manufacturing sector here saw revenue surge by 213% between 2022 and 2024. The approval of the Jiangsu FTZ Open and Innovative Development Plan (August 2025) further solidifies this pole.

• Greater Bay Area (GBA): Provides a unique strategic gateway to global markets, utilizing a regulatory framework that permits the use of Hong Kong-registered drugs in designated mainland hospitals. This provides a low-risk access route for foreign companies to validate products in a market of 86 million people.

The effectiveness of this strategy was unequivocally validated by the market in 2025, with a licensing (BD) deal boom exceeding $87.4 billion in the first eight months. The focus on high-potential sectors like MASH (steatohepatitis) saw over $10.7 billion invested in the FGF21 asset by multinationals like GlaxoSmithKline, Roche, and Novo Nordisk, confirming the international recognition of Chinese innovation. If China consolidates its dominance in this high-value segment, its influence will extend from mass supply to control over future innovation and next-generation therapies.

Geoeconomic Risks and Asymmetric Coercion

This dual dominance (API + Innovation) intensifies Western vulnerability in the trade war. Beijing's strategic goal is to leverage healthcare dependence.

The geoeconomic, supply chain, and legal risks for companies operating in China are acute:

1. Supply Chain Vulnerabilities. Reliance on essential APIs (e.g., 97% of US antibiotics) exposes the West to strategic disruption. This risk is compounded by documented quality concerns (e.g., the 2024 FDA indictment against Sichuan Deebio).

2. Legal Asymmetries and Mercantilism. Foreign enterprises face systemic distortions and tactics of predatory mercantilism. Chinese legislation, including the National Security Law, codifies asymmetries favoring domestic firms and compels companies to share sensitive data with the government. This creates a "critically unbalanced" market relationship.

3. Data and Surveillance Risk. The legal framework facilitates the illicit collection of complex health and genomic data (e.g., by government-connected entities like BGI). This data is transformed into a geopolitical tool, used as intelligence to fuel Chinese AI-driven innovation and for surveillance, turning patient privacy into a national security threat.

The consolidation of Chinese dominance across innovation, supply chain, and data represents a definitive threat to global economic security and public well-being.

Extrema Ratio: Who We Are? 

Extrema Ratio is comprised of Gabriele and Nicola Iuvinale, OSINT Analysts with over 25 years of experience as corporate lawyers. What We Do? We provide strategic and security analysis on China, based on rigorous OSINT, to inform and support proactive decision-making.